OBJECTIVE: To compare and analyze the efficacy of enoxaparin sodium and low molecular weight heparin sodium in the treatment of severe pre-eclampsia and the effects on serum lipid peroxides（ LPO）

cystatin C（ CysC） and placental growth factor（ PIGF）. METHODS: Totally 118 patients with severe pre-eclampsia admitted into Zhuzhou Central Hospital from Jan. 2017 to Jan. 2021 were extracted to be divided into the observation group and the control group via the random number table

with 59 cases in each group. The observation group was treated with enoxaparin sodium

while the control group received low molecular weight heparin sodium. Clinical efficacy

blood pressure

coagulation function

LPO

CysC and PIGF and pregnancy outcomes of two groups were observed.RESULTS: The total effective rate of the observation group was 88. 14%（ 52/59）

significantly higher than that of the control group（ 72. 88%

43/59）

and the difference was statistically significant（ P < 0. 05）. Compared with the control group

the observation group had lower levels of systolic blood pressure

diastolic blood pressure

fibrinogen

D-dimer

LPO and CysC

longer time of prothrombin

activated partial thrombin

higher levels of PIGF

longer time of pregnancy

and lower incidence of cesarean section

fetal distress and postpartum hemorrhage after treatment

the differences were statistically significant（ P < 0. 05）. CONCLUSIONS: Enoxaparin sodium is more effective than low molecular weight heparin sodium in the treatment of severe preeclampsia

with better blood pressure control

more obvious anticoagulation and improvement of renal function

and lower incidence of adverse pregnancy outcomes.